Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Repeated GON Injections in CCH

Phase 3

Recruiting

Conditions: Cluster Headache

Interventions: Drug: Saline solution
Drug: Methylprednisolone

First Posted Date: 2022-04-12

Last Posted Date: 2023-12-26

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 50

Registration Number: NCT05324748

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇳🇱
Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Dexamethasone
Biological: Inotuzumab Ozogamicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Methylprednisolone
Biological: Rituximab
Drug: Prednisone
Drug: Mercaptopurine
Drug: Doxorubicin

First Posted Date: 2022-03-31

Last Posted Date: 2024-08-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 66

Registration Number: NCT05303792

Locations: 🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸
Marshfield Medical Center - Weston, Weston, Wisconsin, United States
🇺🇸
Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States

and more 61 locations

The Effect of Different Intra-articular Injections Primary Gonarthrosis

Not Applicable

Completed

Conditions: Gonarthrosis; Primary

Interventions: Drug: Tenoxicam 20 Mg Powder for Solution for Injection Vial
Drug: Methylprednisolone
Drug: Saline

First Posted Date: 2022-03-23

Last Posted Date: 2022-03-23

Lead Sponsor: Nevsehir Haci Bektas Veli University

Target Recruit Count: 80

Registration Number: NCT05291793

Locations: 🇹🇷
Nevşehir State Hospital, Nevşehir, Turkey
🇹🇷
Kartal Lutfi Kırdar State Hospital, İstanbul, Turkey
🇹🇷
Acıbadem Kozyatağı Hospital, Istanbul, Kozyatağı, Turkey

Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP

Phase 1

Recruiting

Conditions: Malignant Tumor
Pneumonitis

Interventions: Drug: Methylprednisolone
Drug: Pirfenidone, methylprednisolone

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: Zhou Chengzhi

Target Recruit Count: 48

Registration Number: NCT05280873

Locations: 🇨🇳
Zhou Chengzhi, Guangzhou, Guangdong, China

CORTERAS STUDY: The Effect of Corticosteroids on Early Recovery After Major Surgery in Elderly Patients

Phase 4

Recruiting

Conditions: Inflammatory Response
Weakness, Muscle

Interventions: Drug: NaCl 0.9%
Drug: Methylprednisolone

First Posted Date: 2022-02-02

Last Posted Date: 2024-04-11

Lead Sponsor: Ziekenhuis Oost-Limburg

Target Recruit Count: 672

Registration Number: NCT05220319

Locations: 🇧🇪
Ziekenhuis Oost-Limburg, Genk, Belgium

MYTHS - MYocarditis THerapy With Steroids

Phase 3

Recruiting

Conditions: Myocarditis Acute

Interventions: Drug: saline solution
Drug: Methylprednisolone

First Posted Date: 2021-12-09

Last Posted Date: 2024-12-13

Lead Sponsor: Niguarda Hospital

Target Recruit Count: 288

Registration Number: NCT05150704

Locations: 🇦🇹
Medical University of Graz, Graz, Austria
🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇦🇹
Medical University of Wien, Wien, Austria

and more 47 locations